Triple-negative breast cancer lacks key receptors, requiring chemotherapy, immunotherapy, surgery, and radiation, with treatment tailored to cancer stage. Early-stage TNBC treatment often involves ...

A gene that is typically active only in reproductive cells may hold the key to new treatments for triple negative breast cancer, according to new research published in the journal Nature ...

Two major studies are looking at moving sacituzumab govitecan earlier for metastatic triple-negative breast cancer.

Patients diagnosed with metastatic triple-negative breast cancer, one of the most aggressive and treatment-resistant forms of ...

While triple-negative breast cancer (TNBC) is generally an aggressive subtype, it is highly heterogeneous, with a subset of patients having a more favorable biology and high responsiveness to systemic ...

The FDA has approved sacituzumab govitecan-hziy as first-line therapy for adults with unresectable locally advanced or ...

In almost all solid tumors - i.e. cancers with a solid tissue structure - the detection of tumor cells in the lymph nodes is considered a decisive marker for the progression of the disease. Lymph node ...

Hearing the words "triple-negative breast cancer" (TNBC) can be overwhelming. It's a diagnosis that sounds heavy — not just because breast cancer itself is frightening, but because this particular ...

Triple-negative breast cancer—the most aggressive breast cancer subtype—has a high propensity for brain metastases, with ...

The treatment paradigm of stage II to III triple-negative breast cancer (TNBC) is rapidly evolving, with the recent incorporation of pembrolizumab to neoadjuvant chemotherapy improving disease ...